Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Assets Average (2016 - 2026)

Neurocrine Biosciences filings provide 15 years of Assets Average readings, the most recent being $4.4 billion for Q4 2025.

  • On a quarterly basis, Assets Average rose 22.66% to $4.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.4 billion, a 22.66% increase, with the full-year FY2025 number at $4.2 billion, up 19.8% from a year prior.
  • Assets Average hit $4.4 billion in Q4 2025 for Neurocrine Biosciences, up from $4.1 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $4.4 billion in Q4 2025 to a low of $1.8 billion in Q1 2021.
  • Median Assets Average over the past 5 years was $2.6 billion (2023), compared with a mean of $2.8 billion.
  • Biggest five-year swings in Assets Average: increased 4.41% in 2022 and later surged 42.2% in 2024.
  • Neurocrine Biosciences' Assets Average stood at $2.0 billion in 2021, then rose by 10.33% to $2.3 billion in 2022, then surged by 35.18% to $3.0 billion in 2023, then rose by 18.92% to $3.6 billion in 2024, then grew by 22.66% to $4.4 billion in 2025.
  • The last three reported values for Assets Average were $4.4 billion (Q4 2025), $4.1 billion (Q3 2025), and $3.8 billion (Q2 2025) per Business Quant data.